Evaluation of the efficacy of Propionyl-L-carnitine versus pulsed muscular compressions in diabetic and non-diabetic patients affected by obliterating arteriopathy Leriche stage II

International Angiology

Volumn 27, Issue 3, 2008, Pages 253-259

  Riccioni, C ^a   Sarcinella, R ^a   Palermo, G ^a   Izzo, A ^a   Liguori, M ^a   Koverech, A ^b   Messano, M ^b   Virmani, Ashraf ^b  

^a NUOVO REGINA MARGHERITA HOSPITAL   (Italy)

^b Sigma Tau SpA   (Italy)

Author keywords

Arterial occlusive diseases; Diabetes mellitus, type 2; Intermittent claudication; Microcirculation; Mitochondria; Propionyl L carnitine

Indexed keywords

CARNITINE; FATTY ACID; PROPIONYL COENZYME A; PROPIONYLCARNITINE; SODIUM CHLORIDE; CARDIOVASCULAR AGENT; DRUG DERIVATIVE;

ADULT; ARTERIOSCLEROSIS; ARTERY DISEASE; ARTERY OCCLUSION; ARTICLE; BLOOD SAMPLING; CELL METABOLISM; CITRIC ACID CYCLE; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; COMPRESSION THERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DIABETIC PATIENT; DRUG EFFICACY; DRUG TRANSFORMATION; FATTY ACID TRANSPORT; FEMALE; HUMAN; IMPEDANCE PLETHYSMOGRAPHY; LERICHE SYNDROME; MALE; MONOTHERAPY; OUTCOME ASSESSMENT; PATIENT SELECTION; PHYSIOTHERAPY; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; TREADMILL EXERCISE; TREATMENT DURATION; WALKING; AGED; COMPARATIVE STUDY; CONVALESCENCE; HOSPITALIZATION; INTERMITTENT CLAUDICATION; INTERMITTENT PNEUMATIC COMPRESSION DEVICE; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; TIME; TREATMENT OUTCOME;

AGED; ARTERIAL OCCLUSIVE DISEASES; CARDIOVASCULAR AGENTS; CARNITINE; COMBINED MODALITY THERAPY; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INTERMITTENT CLAUDICATION; INTERMITTENT PNEUMATIC COMPRESSION DEVICES; MALE; MIDDLE AGED; QUALITY OF LIFE; RECOVERY OF FUNCTION; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; WALKING;

EID: 47249155341     PISSN: 03929590     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Brevetti G, Corrado S, Martone VD, Di Donato A, Silvestro A, Vanni L. Microcirculation and tissue metabolism in peripheral arterial disease. Clin Hemorheol Microcirc 1999;21:245-54.
2. Wisernan LR, Brogden RN. Propionyl-L-carnitine. Drugs Aging 1998;12:243-8.
3. Binienda Z, Virmani A, The mitochondriotropic effects of L-carnitine and its esters in the central nervous system. Curr Med Chem 2003;3:275-82.
4. Cipolla MJ, Nicoloff A, Rebello T, Amato A, Porter JM. Propionyl-L-carnitine dilates human subcutaneous arteries through an endothelum dependent mechanism. J Vasc Surg 1998;29:1097-103.
5. Ferrari R, Merli E, Cicchitelli G, Mele D, Fucili A, Ceconi C. Therapeutic effects of L-camitine and propionyl-L-carnitine on cardiovascular diseases: a review. Ann N Y Acad Sci 2004;1033:79-91.
6. Siliprandi N, Di Lisa F. Menabo R. Propionyl-L-carnitine: biochemical significance and possible role in cardiac metabolism. Cardiovasc Drugs Ther 1991;5 Suppl 1:11-5.
7. Brevetti G, Diehm C, Lambert D. European multicenter study on propionyl-l-carnitine in intermittent claudication. J Am Coll Cardiol 1999;34:1618-24.
8. Dal Lago A, De Martini D, Flore R, Gaetani E, Gasbarrini A, Gerardino L et al. Effects of propionyl-L-carnitine on peripheral arterial obliterative disease of the lower limbs: a double blind clinical trial. Drugs Expfl Clin. Res 1999;25:29-36.
9. Steimberg J. Cardiosynchronous limb compression: effect on non invasive vascular test and clinical course of the ischemic limb. Angiology 1992;43:3-61.
10. Allegra C, Bartolo M Jr, Martocchia R. Effetti terapeutici del Vascupump in pazienti con arteriopatia al II stadio B di Fontaine. Minerva Cardioangiol 2000;48:1-6.
11. Milio G, Novo G, Ferrara F, Raimondi F, Novo S. Changes of arterial hemodynamics in patients with type 2 diabetes mellitus or impaired glucose tolerance. Int Angiol 2006;25:73.
12. Andreozzi GM, Signorelli SS, Cacciaguerra G, Di Pino L, Martini R, Monaco S et al. Three-month therapy with calcium-heparin in comparison with ticlopidine in patients with peripheral arterial occlusive disease at Leriche-Fontaine IIb class. Angiology 1993;44:307-13.
13. Macchione C, Antignani PL, Longo F, Nicosia PM, Poli L. La pletismografia. Torino: Centro Scientifico Ed.; 1988.
14. Brevetti G, Angelini C, Rosa M, Carrozzo R, Perna S, Corsi M et al. Muscle carnitine deficiency in patients with severe peripheral vascular disease. Circulation 1991;84:1490-5.
15. Barker GA, Green S, Askew CD, Green AA, Walker PJ. Effect of propionyl-L-carnitine on exercise performance in peripheral arterial disease. Med Sci Sports Exerc 2001;33:1415-22.
16. Hiatt WR. Carnitine and peripheral arterial disease. Ann N Y Acad Sci 2004;1033:92-8.
17. Riccioni C, Sarcinella R Izzo A, Palermo G. Effects of L-propionyl carnitine in patients affected by peripheral arteriopathy. Int Angiol 2004;23:207.
18. Kakkos SK, Nicolaides AN, Griffin M, Geroulakos G. Comparison of two intermittent pneumatic compression systems. A hemodynamic study. Int Angiol 2005;24:330.
19. lis KT, Nicolaides AN. Effect of intermittent pneumatic compression of foot and calf on walking distance, hemodynamics, and quality of life in patients with arterial claudication: a prospective randomized controlled study with 1-year follow-up. Ann Surg 2005;241:431-41.
20. Creager MA. Medical management of peripheral arterial disease. Cardiol Rev 2001;9:238-45.